Opendata, web and dolomites


Early detection of tumor DNA in liquid biopsies as a biomarker of cancer recurrence

Total Cost €


EC-Contrib. €






 ONCOTECT project word cloud

Explore the words cloud of the ONCOTECT project. It provides you a very rough idea of what is the project "ONCOTECT" about.

death    recurrent    head    routine    ct    workflow    reliably    clinical    first    diagnostics    detection    licensing    sme    market    examination    mutations    regulatory    methodology    superior    genes    dna    integration    detects    start    breaking    biopsies    90    liquid    commercialization    standard    cyclomics    diagnostic    faster    relative    underlying    hnc    proprietary    inexpensive    screening    monitoring    tp53    considerable    cancer    bv    treatment    ivd    carry    initial    delays    oncogenic    competing    disease    operate    time    full    circulating    oncotect    cohort    programs    blood    sensitive    unable    spectrum    fto    ambition    gene    types    rates    ground    remission    dutch    survival    feasibility    tumor    critical    vitro    samples    sequencing    fast    neck    lower    care    radiological    company    ultra    accurate    quality    opportunity    encompassing    patients    lesions    freedom    proof    decision    strategy    recurrence    obtain    leveraging    detecting    detect    kit    vision    assay    disrupt   

Project "ONCOTECT" data sheet

The following table provides information about the project.


Organization address
address: MOSKEEPLEIN 82
postcode: 3531 BX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYCLOMICS BV NL (UTRECHT) coordinator 50˙000.00


 Project objective

Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies). The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods. Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Cancersensing (2019)

A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

HAC (2019)


Read More